Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 4/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491422 | 0.98 | PPARG (0.51) | PPARGPDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6500098 | 0.97 | PPARG (0.50) | PPARGPDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6498744 | 0.96 | PPARG (0.51) | PPARGPDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6491237 | 0.93 | FFAR1 (0.49) | PPARGPDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6487612 | 0.93 | PPARG (0.51) | PPARGMCL1ALOX5APPLA2G4B | |
| SCHEMBL6501485 | 0.93 | PPARG (0.45) | PPARGPDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6497461 | 0.91 | PPARG (0.49) | PPARGPDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL7199173 | 0.91 | PPARG (0.45) | PPARGPDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6501536 | 0.90 | PPARG (0.52) | PPARGPDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6497975 | 0.90 | PPARG (0.44) | PPARGPDE3BPDE3AP2RY12PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARG 233/4885PDE3B 411/4885PDE3A 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.